Physician profile
Noah J Lee
NPI 1275559106
$1,164,532.79
in general payments reported to CMS, 2019-2025
65 companies · $189K in 2025
The $189K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219K · 2020: $67K · 2021: $94K · 2022: $171K · 2023: $177K · 2024: $247K · 2025: $189K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $477K · Travel and Lodging: $64K · Food and Beverage: $29K · Consulting Fee: $26K · Honoraria: $9,485 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $477,494.50 |
| Travel and Lodging | $64,326.40 |
| Food and Beverage | $28,636.93 |
| Consulting Fee | $25,956.00 |
| Honoraria | $9,485.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,631.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $490,183.31 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $305,095.13 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Janssen Products, Lp | $88,981.68 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $69,339.68 | 2020-2025 | Serostim, Serostim |
| Abbvie INC. | $56,354.61 | 2019-2025 | |
| Theratechnologies INC. | $38,229.38 | 2019-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Janssen Pharmaceuticals, INC | $34,121.42 | 2019-2024 | Xarelto |
| Napo Pharmaceuticals INC | $32,361.41 | 2019-2025 | Mytesi |
| Merck Sharp & Dohme LLC | $23,183.03 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Amgen INC. | $13,557.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $2,125.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,409.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Biotech, INC. | $1,385.92 | 2019-2023 | Symtuza, Prezcobix |
| Glaxosmithkline, LLC. | $1,189.98 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $771.27 | 2020-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.